Something old and something new: An update on the amazing repertoire of bacteriocins produced by Streptococcus salivarius

Probiotics and Antimicrobial Proteins

Volumn 2, Issue 1, 2010, Pages 37-45

  Wescombe, Philip A ^a   Heng, Nicholas C K ^a   Burton, Jeremy P ^a   Tagg, John R ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Bacterial interference; Bacteriocin like inhibitory substance; Bacteriocins; BLIS; Probiotics; Rheumatic fever; Streptococcal pharyngitis; Streptococcus pyogenes; Streptococcus salivarius

Indexed keywords

BACTERIOCIN; LANTIBIOTIC; PLASMID DNA; PROBIOTIC AGENT; SALIVARICIN 9; SALIVARICIN A; SALIVARICIN A1; SALIVARICIN A2; SALIVARICIN A3; SALIVARICIN A4; SALIVARICIN A5; SALIVARICIN B; SALIVARICIN G32; STREPTIN; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; COMMENSAL; CONTROLLED STUDY; HABITAT; MOUTH FLORA; NATURAL HOST; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STREPTOCOCCUS SALIVARIUS; TONGUE;

BACTERIA (MICROORGANISMS); STREPTOCOCCUS PYOGENES; STREPTOCOCCUS SALIVARIUS;

EID: 77953870385     PISSN: 18671306     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12602-009-9026-7     Document Type: Article

References (60)

1. Andrews S (1997). Investigation of factors influencing the implantation of Streptococcus salivarius strain Min5 onto the human tongue. Department of Microbiology. Dunedin, University of Otago. BMedSci: 87.
2. Asaduzzaman SM, Nagao J et al (2009) Nukacin ISK-1, a bacteriostatic lantibiotic. Antimicrob Agents Chemother 53(8): 3595-3598.
3. Balakrishnan M, Simmonds RS et al (2001) Diverse activity spectra of bacteriocin-like inhibitory substances having activity against mutans streptococci. Caries Res 35(1): 75-80.
4. Bishop CJ, Aanensen DM et al (2009) Assigning strains to bacterial species via the internet. BMC Biol 7: 3.
5. Bisno AL (1991) Group A streptococcal infections and acute rheumatic fever. N Engl J Med 325(11): 783-793.
6. Bouwer A (2006) Activation of natural killer cells by dendritic cells stimulated by gram-positive bacterial cell wall components. Department of Microbiology and Immunology. Dunedin, University of Otago. BSc (Hons): 41.
7. Burton JP, Chilcott CN et al (2006) A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters. J Appl Microbiol 100(4): 754-764.
8. Burton JP, Wescombe PA et al (2006) Safety assessment of the oral cavity probiotic Streptococcus salivarius K12. Appl Environ Microbiol 72(4): 3050-3053.
9. Carapetis, J. R. (2004) Group A streptococcal vaccine development: current status and issues of relevance to less developed countries. WHO/FCH/CAH/05. 09. Geneva: World Health Organization. Volume, DOI:.
10. Carapetis JR (2007) Rheumatic heart disease in developing countries. N Engl J Med 357(5): 439-441.
11. Carapetis JR, Steer AC et al (2005) The global burden of group A streptococcal diseases. Lancet Infect Dis 5(11): 685-694.
12. Carlsson J, Grahnen H et al (1970) Early establishment of Streptococcus salivarius in the mouths of infants. J Dent Res 49: 415-418.
13. Chilcott CN, Crowley L et al (2005) Elevated levels of interferon gamma in human saliva following ingestion of Streptococcus salivarius K12. Joint meeting of New Zealand Microbiological Society and New Zealand Biochemistry and Molecular Biology, Dunedin.
14. Chilcott CN and Tagg JR (2007) Antimicrobial composition. Patent. USA.
15. Cosseau C, Devine DA et al (2008) The commensal Streptococcus salivarius K12 downregulates the innate immune responses of human epithelial cells and promotes host-microbe homeostasis. Infect Immun 76(9): 4163-4175.
16. Dale JB (2008) Current status of group A streptococcal vaccine development. Adv Exp Med Biol 609: 53-63.
17. Delorme C, Poyart C et al (2007) Extent of horizontal gene transfer in evolution of Streptococci of the salivarius group. J Bacteriol 189(4): 1330-1341.
18. Dempster RP, Tagg JR (1982) "The production of bacteriocin-like substances by the oral bacterium Streptococcus salivarius. Arch Oral Biol 27(2): 151-157.
19. Dierksen KP, Moore CJ et al (2007) "The effect of ingestion of milk supplemented with salivaricin A-producing Streptococcus salivarius on the bacteriocin-like inhibitory activity of streptococcal populations on the tongue. FEMS Microbiol Ecol 59(3): 584-591.
20. Dierksen KP and Tagg J (2000) The influence of indigenous bacteriocin-producing Streptococcus salivarius on the acquisition of Streptococcus pyogenes by primary school children in Dunedin, New Zealand. Streptococci and streptococcal diseases entering the new millennium. DR Martin and TJ Auckland, Securacopy: 81-85.
21. Dodd SJ (1999) A saliva model to demonstrate Streptococcus salivarius BLIS production and characterisation of salivaricin MPS. University of Otago, Dunedin.
22. Favier CF, Vaughan EE et al (2002) Molecular monitoring of succession of bacterial communities in human neonates. Appl Environ Microbiol 68(1): 219-226.
23. Georgalaki MD, van Den Berghe E et al (2002) Macedocin, a food-grade lantibiotic produced by Streptococcus macedonicus ACA-DC 198. Appl Environ Microbiol 68(12): 5891-5903.
24. Hyink O, Wescombe PA et al (2007) Salivaricin A2 and the novel lantibiotic salivaricin B are encoded at adjacent loci on a 190-kilobase transmissible megaplasmid in the oral probiotic strain Streptococcus salivarius K12. Appl Environ Microbiol 73(4): 1107-1113.
25. Hynes WL, Friend VL et al (1994) Duplication of the lantibiotic structural gene in M-type 49 group A streptococcus strains producing streptococcin A-M49. Appl Environ Microbiol 60(11): 4207-4209.
26. Hynes WL, Tagg JR (1984) Bacteriocin-like activity of an M-type 25 group A Streptococcus. Proc Univ Otago Med Sch 62: 109-110.
27. Hynes WL, Tagg JR (1985) Production of broad-spectrum bacteriocin-like activity by group A streptococci of particular M-types. Zentralbl Bakteriol Mikrobiol Hyg [A] 259(2): 155-164.
28. Ivanova I, Miteva V et al (1998) Characterization of a bacteriocin produced by Streptococcus thermophilus 81. Int J Food Microbiol 42(3): 147-158.
29. Johnson DW, Tagg JR et al (1979) Production of a bacteriocin-like substance by group-A streptococci of M-type 4 and T-pattern 4. J Med Microbiol 12(4): 413-427.
30. Karaya K, Shimizu T et al (2001) New gene cluster for lantibiotic streptin possibly involved in streptolysin S formation. J Biochem (Tokyo) 129(5): 769-775.
31. Kazor CE, Mitchell PM et al (2003) Diversity of bacterial populations on the tongue dorsa of patients with halitosis and healthy patients. J Clin Microbiol 41(2): 558-563.
32. Kennedy KL (1995) Saliva-dependent autoinhibitory activity of Streptococcus salivarius strain 6. Department of Microbiology. Dunedin, University of Otago. BSc (Hons): 43.
33. Lennon D (2004) Acute rheumatic fever in children: recognition and treatment. Paediatr Drugs 6(6): 363-373.
34. Lester H (2006) The relationship between β-haemolysis and bacteriocin-like inhibitory substance (BLIS) production of Streptococcus salivarius. Department of Microbiology. Dunedin, University of Otago. BSc (Hons): 43.
35. Lewus CB, Sun S et al (1992) Production of an amylase-sensitive bacteriocin by an atypical Leuconostoc paramesenteroides strain. Appl Environ Microbiol 58(1): 143-149.
36. Liljemark WF, Gibbons RJ (1973) Suppression of Candida albicans by human oral streptococci in gnotobiotic mice. Infect Immun 8(5): 846-849.
37. Loesche WJ, Kazor C (2002) Microbiology and treatment of halitosis. Periodontol 28: 256-279.
38. MacFarlane TW (1984) The oral ecology of patients with severe Sjogren's syndrome. Microbios 41(160): 99-106.
39. Papadelli M, Karsioti A et al (2007) Characterization of the gene cluster involved in the biosynthesis of macedocin, the lantibiotic produced by Streptococcus macedonicus. FEMS Microbiol Lett 272(1): 75-82.
40. Phelps HA, Neely MN (2007) SalY of the Streptococcus pyogenes lantibiotic locus is required for full virulence and intracellular survival in macrophages. Infect Immun 75(9): 4541-4551.
41. Power DA, Burton JP et al (2008) Preliminary investigations of the colonisation of upper respiratory tract tissues of infants using a paediatric formulation of the oral probiotic Streptococcus salivarius K12. Eur J Clin Microbiol Infect Dis 27(12): 1261-1263.
42. Robson CL, Wescombe PA et al (2007) Isolation and partial characterization of the Streptococcus mutans type AII lantibiotic mutacin K8. Microbiology 153(Pt 5): 1631-1641.
43. Ross KF, Ronson CW et al (1993) Isolation and characterization of the lantibiotic salivaricin A and its structural gene salA from Streptococcus salivarius 20P3. Appl Environ Microbiol 59(7): 2014-2021.
44. Russell C, Tagg JR (1981) Role of bacteriocin during plaque formation by Streptococcus salivarius and Streptococcus sanguis on a tooth in an artificial mouth. J Appl Bacteriol 50(2): 305-313.
45. Sanders CC, Sanders WE (1982) Enocin: an antibiotic produced by Streptococcus salivarius that may contribute to protection against infections due to Group A Streptococci. J Infect Dis 146: 683-690.
46. Simpson WJ, Ragland NL et al (1995) A lantibiotic gene family widely distributed in Streptococcus salivarius and Streptococcus pyogenes. Dev Biol Stand 85: 639-643.
47. Tagg JR (1991) Studies of "BLIS-ful" oral bacteria. N Z Dent J 87(387): 14-16.
48. Tagg JR, Bannister LV (1979) "Fingerprinting" beta-haemolytic streptococci by their production of and sensitivity to bacteriocin-like inhibitors. J Med Microbiol 12(4): 397-411.
49. Tagg JR, Pybus V et al (1983) Application of inhibitor typing in a study of the transmission and retention in the human mouth of the bacterium Streptococcus salivarius. Arch Oral Biol 28(10): 911-915.
50. Tagg JR, Ragland NL et al (1990) A longitudinal study of Lancefield group A streptococcus acquisitions by a group of young Dunedin schoolchildren. N Z Med J 103(897): 429-431.
51. Tagg JR, Russell C (1981) Bacteriocin production by Streptococcus salivarius strain P. Can J Microbiol 27(9): 918-923.
52. Tompkins GR, Tagg JR (1987) Bacteriocin-like inhibitory activity associated with beta-hemolytic strains of Streptococcus salivarius. J Dent Res 66(8): 1321-1325.
53. Tompkins GR, Tagg JR (1989) The ecology of bacteriocin-producing strains of Streptococcus salivarius. Microb Ecol Health Dis 2: 19-28.
54. Upton M, Tagg JR et al (2001) Intra- and interspecies signaling between Streptococcus salivarius and Streptococcus pyogenes mediated by SalA and SalA1 lantibiotic peptides. J Bacteriol 183(13): 3931-3938.
55. Walls T, Power D et al (2003) Bacteriocin-like inhibitory substance (BLIS) production by the normal flora of the nasopharynx: potential to protect against otitis media? J Med Microbiol 52(Pt 9): 829-833.
56. Wang Y (2007) Purification and characterisation of novel bacteriocin salivaricin MPS. Department of Biochemistry. Dunedin, University of Otago. PGDipSci: 39.
57. Wescombe PA (2002) Characterisation of lantibiotics produced by Streptococcus salivarius and Streptococcus pyogenes. Department of Microbiology and Immunology. Dunedin, University of Otago: 324.
58. Wescombe PA, Burton JP et al (2006) Megaplasmids encode differing combinations of lantibiotics in Streptococcus salivarius. Antonie van Leeuwenhoek 90(3): 269-280.
59. Wescombe PA, Tagg JR (2003) Purification and characterization of streptin, a type A1 lantibiotic produced by Streptococcus pyogenes. Appl Environ Microbiol 69(5): 2737-2747.
60. Wescombe PA, Upton M et al (2006) Production of the lantibiotic salivaricin A and its variants by oral streptococci and use of a specific induction assay to detect their presence in human saliva. Appl Environ Microbiol 72(2): 1459-1466.